Health Care · Pharmaceutical Preparations

PRAX Praxis Precision Medicines, Inc. SEC Filings & Insider Trading Activity 2026

company
CIK 1689548116 filings
Russell 2000

PRAX at a glance

Praxis Precision Medicines, Inc. (PRAX, SEC CIK 1689548) filed its latest 10-K annual report on February 19, 2026, a 10-Q quarterly report on November 9, 2026, an 8-K current report on November 12, 2026 and Form 4 insider filings as recently as November 18, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.

  • For the fiscal year ended December 31, 2025 (FY2025), Praxis Precision Medicines, Inc. (PRAX) reported revenue of $0 (down 100.0% from FY2024) and a net loss of $303.3 million. Diluted EPS was -$13.48.
  • As of September 30, 2026, 32 institutional investment managers tracked by SignalX reported holding Praxis Precision Medicines, Inc. (PRAX) shares worth $3.2 billion in 13F-HR filings.
  • The most recent insider open-market sale reported on Form 4 was by DeSimone Jill on June 24, 2026 of 683 shares at $306.77 per share.

Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).

Revenue · FY2025
$0
−100.0% vs prior year
Insiders · 90 days
0 buys · 0 sells
No open-market trades
13F holders
32 funds
$3.2B · +0 vs prior quarter
Latest 8-K
Nov 12, 2026
Item 7.01 · Item 8.01

AI 10-K Annual Report Analysis

Latest 10-K, fiscal year ended Dec 31, 2025

Full analysis →

Business Overview

  • Core business: Precision neuroscience biopharma developing therapies for CNS disorders from genetic epilepsies via two platforms, Cerebrum™ (small molecules) and Solidus™ (antisense oligonucleotides)
  • New emphasis on clinical development with four clinical-stage candidates; submitted NDAs for ulixacaltamide (essential tremor) and relutrigine (SCN2A-DEE, SCN8A-DEE)
  • Strategic shift to expanded clinical and commercial preparations for NDA-stage assets and ongoing Phase 3 programs (POWER1, POWER2 for vormatrigine) targeting broader epilepsy and CNS disorders
  • Quantitative highlight: ~7 million US essential tremor patients, 54% median seizure reduction in RADIANT vormatrigine Phase 2, 53% placebo-adjusted seizure reduction with relutrigine in EMBOLD Phase 2
  • Noteworthy: FDA granted Breakthrough Therapy Designation for ulixacaltamide and relutrigine; first commercial collaboration in Greater China for ulixacaltamide launched

Risk Factors

  • Regulatory risk: ongoing FDA review of NDAs for ulixacaltamide (essential tremor) and relutrigine (SCN2A and SCN8A DEEs) with uncertain approval timing or outcome
  • Macroeconomic exposure: cash runway extends into 2028 but risks of faster cash burn due to increased R&D, clinical trials, or unexpected costs
  • Supply chain vulnerability: potential delays or failure in manufacturing scale-up or third-party clinical/commercial supply arrangements
  • Competitive risk: failure to address competing technologies or market acceptance risks amid evolving neurology drug landscape
  • Financial risk: accumulated deficit $1.1 billion with net losses $303.3 million in 2025 and $182.8 million in 2024, requiring additional capital raising that could dilute shareholders

Management Discussion & Analysis

  • No revenues reported; focused on R&D and pre-commercial activities with expected substantial operating expense increases
  • Operating losses expected to grow due to advancing clinical trials, commercialization prep, and infrastructure buildout; no margin % disclosed
  • No segment performance breakdown; primary activities in Cerebrum™ and Solidus™ platforms with collaborative IP licensing arrangements
  • Cash, cash equivalents, and marketable securities plus January 2026 follow-on offering proceeds expected to fund operations into 2028; lease and licensing commitments total $1.6M plus milestone payments (e.g., $3.0M to RogCon, $6.9M to Ionis)
  • Risks: high R&D costs, uncertainty of approval and commercialization, potential need for additional capital with dilution risk, market volatility affecting funding access

AI summary of the PRAX 10-K filed . Generated from the filing text; verify against the original.View on SEC EDGARHow to read a 10-K

AI 10-Q Quarterly Report Analysis

Latest 10-Q, quarter ended Sep 30, 2026

Risk Factors

  • No material changes from the December 31, 2025 Form 10-K risk factors
  • Carried-forward risks include clinical development, regulatory approval, commercialization, financing, competition, and intellectual property challenges

Management Discussion & Analysis

  • Revenue $0, unchanged YoY, no product sales since inception
  • Net loss $94.2M vs $73.9M YoY, operating loss $106.9M vs $78.4M
  • R&D $64.2M vs $65.8M, Cerebrum™ highest at $40.4M, Solidus™ $2.8M
  • Cash, equivalents and marketable securities $1.3B, operating cash use $245.4M for nine months
  • Ulixacaltamide PDUFA January 29, 2027, relutrigine updated to December 27, 2026, POWER1 endpoint failure headwind

AI summary of the PRAX 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K

AI 8-K Current Report Analysis

The most recent material events, by 8-K item

Filed Nov 12, 2026Full analysis →

Item 7.01: Regulation FD Disclosure

  • Investor Day presentation disclosed on November 12, 2026, covering Praxis Precision Medicines’ investor-focused updates
  • Presentation available at investors.praxismedicines.com and furnished as Exhibit 99.1

Item 8.01: Other Events

  • Ulixacaltamide targets about 2 million treatment-seeking U.S. ET patients within an estimated 9 million prevalence population
  • Essential3 endpoint sensitivity analyses matched the primary result, supporting the NDA’s evidentiary consistency

Item EX-99.1: Item EX-99.1

  • Investor Day outlines two planned launches: relutrigine on December 27, 2026 and ulixacaltamide on January 29, 2027
  • Ulixacaltamide PDUFA date January 29, 2027, creating a near-term regulatory catalyst in essential tremor
Filed Nov 9, 2026Full analysis →

Item 2.02: Results of Operations and Financial Condition

  • Q3 2026 financial results announced for quarter ended September 30, 2026
  • Press release containing the results furnished as Exhibit 99.1

Item EX-99.1: Item EX-99.1

  • FDA decisions pending for ulixacaltamide on January 29, 2027 and relutrigine on December 27, 2026, key commercialization catalysts
  • Cash and investments $1.3B as of September 30, 2026, supporting operations into 2028 and reducing near-term financing risk
Filed Aug 6, 2026Full analysis →

Item 2.02: Results of Operations and Financial Condition

  • Fiscal results announced for quarter ended June 30, 2026
  • Press release furnished as Exhibit 99.1, containing detailed financial results and management commentary

Item 7.01: Regulation FD Disclosure

  • Updated corporate presentation for investor and analyst meetings as of August 6, 2026
  • Presentation available on Praxis’s investor website and furnished as Exhibit 99.2

Item EX-99.2: Item EX-99.2

  • Four late-stage CNS assets, including two PDUFA dates: relutrigine December 27, 2026 and ulixacaltamide January 2027
  • Portfolio peak-sales potential above $20B, led by ulixacaltamide above $10B and relutrigine above $5B

Item EX-99.1: Item EX-99.1

  • Q2 net loss $83.7M, or $2.87 per share, versus $71.1M and $3.31 in Q2 2025
  • Cash and investments $1.4B, up from $926.1M, extending operations into 2028

AI summaries of PRAX 8-K current reports filed with the SEC. What 8-K item codes mean

SignalX for PRAX

Don't miss the next PRAX filing

  • Alerts as it files. A push when PRAX files an 8-K or an insider trades.
  • Fund moves. Which tracked funds opened, added or cut PRAX, by share count.
  • Ask anything. An AI agent that reads every PRAX filing and answers with sources.

PRAX alerts on your phone. Follow it in the SignalX Android app.

Get it on Google Play

Recent Insider Transactions (Form 4)

Latest reported trades by officers, directors and 10% owners

InsiderTypeDatePrice
Nemiroff AlexANov 13, 2026$278.91
Sniecinski MeganANov 13, 2026$278.91
Mastrocola LaurenANov 13, 2026$278.91
Kelly Timothy EdwinANov 13, 2026$278.91
Souza MarcioGJul 8, 2026-
Souza MarcioGJul 8, 2026-
DeSimone JillSellJun 24, 2026$306.77
DeSimone JillSellJun 24, 2026$305.31

Financial Summary
XBRL

Annual financial summary from SEC XBRL data
MetricFY2023FY2024FY2025
Profitability
Revenue$2.4M$8.6M$0
Operating Income--$200.2M-$326.2M
Net Income-$123.3M-$182.8M-$303.3M
Op. Margin--2340.3%-
Net Margin-5037.9%-2137.5%-
Balance Sheet
Total Assets-$483.1M$937.9M
Equity-$445.4M$878.1M
ROE--41.0%-34.5%
Per Share
EPS$-18.69$-10.21$-13.48
Cash Flow
Operating CF-$111.1M-$131.8M-$249.1M
CapEx-$0$56K

Source: XBRL data in Praxis Precision Medicines, Inc. (PRAX)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →

13F Fund Holdings: Quarterly Trend

Latest: Q3 2026

Aggregate PRAX share value held by 13F filers tracked by SignalX, by quarter.

Quarterly totals table
PRAX shares held by 13F filers tracked by SignalX, by quarter
QuarterFundsTotal value
Q3 202632$3.15B
Q2 202632$4.24B
Q1 202630$3.54B
Q4 202529$2.81B
Q3 202523$397.9M
Q2 202521$321.3M
Q1 202520$172.1M
Q4 202418$239.4M
Position changes: Q2 2026 → Q3 2026
Top Buyers
Top Sellers
New Positions
Closed Positions

Source: 13F-HR filings on SEC EDGAR (aggregated from 205 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work

PRAX filing archive

AI analysis pages for each 10-K, 10-Q and 8-K

Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4

FormFiling dateAnalysisSEC
4Nov 18, 2026--
4Nov 18, 2026--
4Nov 18, 2026--
4Nov 18, 2026--
8-KNov 12, 2026Analysis-
10-QNov 9, 2026Analysis
8-KNov 9, 2026Analysis-
10-QAug 6, 2026Analysis
8-KAug 6, 2026Analysis-
4Jul 8, 2026--
8-KJul 7, 2026Analysis-
8-KJul 2, 2026Analysis-
8-KJun 29, 2026Analysis-
4Jun 26, 2026--
8-KJun 22, 2026Analysis-
4Jun 12, 2026--
4Jun 12, 2026--
4Jun 12, 2026--
4Jun 12, 2026--
4Jun 12, 2026--
4Jun 12, 2026--
8-KJun 12, 2026Analysis-
4Jun 12, 2026--
4Jun 12, 2026--
8-KJun 1, 2026Analysis

Related Health Care companies

All Health Care →

PRAX SEC filings: frequently asked questions

Which institutions hold PRAX stock?

As of September 30, 2026, the largest Praxis Precision Medicines, Inc. (PRAX) holders among the 13F filers tracked by SignalX were BlackRock ($650.3 million), Vanguard Portfolio Management LLC ($380.0 million), Vanguard Capital Management LLC ($357.9 million), State Street Corp ($304.1 million), Bank of America Corp ($259.4 million). 13F-HR reports are filed up to 45 days after each quarter ends.

What was PRAX's revenue in fiscal year 2025?

For the fiscal year ended December 31, 2025 (FY2025), Praxis Precision Medicines, Inc. (PRAX) reported revenue of $0 (down 100.0% from FY2024) and a net loss of $303.3 million. Diluted EPS was -$13.48. The figures come from the XBRL data in the 10-K.

What are the main risks in PRAX's latest 10-K?

In the 10-K filed February 19, 2026, Praxis Precision Medicines, Inc. (PRAX) flagged: Regulatory risk: ongoing FDA review of NDAs for ulixacaltamide (essential tremor) and relutrigine (SCN2A and SCN8A DEEs) with uncertain approval timing or outcome. Macroeconomic exposure: cash runway extends into 2028 but risks of faster cash burn due to increased R&D, clinical trials, or unexpected costs. (AI summary of the Risk Factors section.)

What did PRAX report in its latest 8-K?

Praxis Precision Medicines, Inc. (PRAX) filed an 8-K on November 12, 2026 reporting Item 7.01 (Regulation FD Disclosure) and Item 8.01 (Other Events). Investor Day presentation disclosed on November 12, 2026, covering Praxis Precision Medicines’ investor-focused updates.

What are the latest PRAX SEC filings?

Praxis Precision Medicines, Inc. (PRAX) filed its latest 10-K annual report on February 19, 2026, a 10-Q quarterly report on November 9, 2026, an 8-K current report on November 12, 2026 and a Form 4 insider filing on November 18, 2026.

What is PRAX's SEC CIK number?

Praxis Precision Medicines, Inc. (PRAX)'s SEC Central Index Key (CIK) is 1689548. EDGAR lists every PRAX filing under that number.

Ask anything about PRAX

The research agent reads PRAX's filings, financials, insider trades and 13F holders, then answers with sources.